Clinical trials: Weight Maintenance
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency.
- Trial name
- NCT00261833
- Testing
- Alpha1-proteinase inhibitor
- Where
- 28 sites in United States, Australia and 11 more
- Volunteers
- 180 people
- Sponsor
- CSL Behring
Overweight , Obesity
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese…
- Trial name
- NCT07804797
- Testing
- MWN109 1, MWN109 2
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight
Excessive body weight is becoming a concern around the world, for example over half of the American adult population is overweight or obese.
- Trial name
- NCT00502658
- Testing
- Dietary supplement containing vitamins, minerals, and herbs, Shakes with nutrients and herbs, Control dietary supplement
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Weight Trajectory
Gamma-linolenic Acid Supplementation Study
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain.
- Trial name
- GLASS (NCT04481724)
- Testing
- gamma-linolenic acid
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- Virta Health
Obesity
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss.
- Trial name
- TRIUMPH-6 (NCT06859268)
- Testing
- Retatrutide
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Obesity
Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects
The purpose of this 2-stage intervention study is to investigate the effect of a novel nutraceutical (containing tetrahydro iso-alpha acids derived from hops) on weight loss and weight loss maintenance in obese participants.
- Trial name
- NCT01656681
- Testing
- THIAA
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- MetaProteomics LLC
Obesity, Weight Loss
Longitudinal Effects of a Commercial Digital Weight Management Program on Weight Loss
This randomized controlled trial (RCT) will test how well a fully remote weight management program (Noom Weight) helps adults with overweight or obesity (BMI 25-45) achieve weight loss in both the short-term (16 weeks) and the…
- Trial name
- NCT06666842
- Testing
- Noom Weight, Educational Control
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- Noom Inc.
Obesity
Use of Radiofrequency Ablation for RGB Salvage
The present study will assess the feasibility of using endoscopic radiofrequency ablation (RFA) to treat the gastric pouch and stoma with the intent to cause tissue contraction and decreased compliance after a failed Roux-en-Y…
- Trial name
- NCT01910688
- Testing
- RFA treatment
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Overweight, Obesity
Effect of Soy Protein and Colorado Diet on Weight Loss and Maintenance
Dietary protein is a key element of most effective weight loss regimens. This study will investigate the effects of consuming soy protein on body composition and cardiometabolic health within the context of an effective weight…
- Conditions
- Overweight, Obesity, Weight Loss
- Trial name
- NCT02380963
- Testing
- Colorado Diet with soy protein foods., Colorado Diet with monetary payments
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- DuPont Nutrition and Health
Stress Urinary Incontinence (SUI)
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years.
- Trial name
- SaHARA (NCT06862648)
- Testing
- Acoustic Stimulation Therapy Device
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- Acoustic Wave Cell Therapy, Inc.
Obesity, Health Behavior
DEMETRA - ADVICE-002-2022
The purpose of this study is to evaluate the safety and performance of DTXO App in improving weight loss and weight-loss maintenance in obese patients exposed to an experimental non-pharmacological treatment program.
- Conditions
- Obesity, Health Behavior, Life Style, Dietary Habits
- Trial name
- NCT05394779
- Testing
- DTXO APP
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Advice Pharma Group srl
Weight Maintenance, Overweight
Litramine in Weight Maintenance
The effect of Litramine on weight loss has previously been studied during a 12-week intervention period with promising results. The present study looks into the effect of weight maintenance using Litramine following initial…
- Conditions
- Weight Maintenance, Overweight, Obese
- Trial name
- NCT01505387
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
Obesity, Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Weight Maintenance
- Trial name
- NCT07553299
- Testing
- VRB-101
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Verdiva Bio Dev Limited
Obesity
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 12 (NCT07503210)
- Testing
- NNC0487-0111
- Where
- 72 sites in United States, Argentina and 10 more
- Volunteers
- 606 people
- Sponsor
- Novo Nordisk A/S
Abdominal Fat, Body Weight
Effects of Whole Grain on Weight Maintenance
Epidemiological studies suggest that whole grain consumption affects measures of obesity including BMI, body fat tissue, and body weight.
- Trial name
- NCT01239147
- Testing
- Diet rich in whole grain, Refined grain
- Where
- France
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Cereal Partners Worldwide
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles